24-hour hotline : 23 922 922
e-mail address : enquiry@tid.gov.hk
Ref. : 101-002-007
28 April 2026
Dear Sirs,
Commercial Information Circular No. 405/2026
Chinese Mainland : Amended “Working Procedures for the Evaluation and Approval of Applications for Conditional Marketing Authorisation for Drugs”
The National Medical Products Administration issued on 22 April 2026 the amended “Working Procedures for the Evaluation and Approval of Applications for Conditional Marketing Authorisation for Drugs”, which took effect on the date of promulgation. Please refer to the Appendix for the working procedures (in Chinese only).
ENQUIRIES
2. If you have any questions on the content of the document mentioned in this circular, please contact the issuing authority of the Mainland. For other questions on this circular, please contact Mainland Branch (I) (tel: 2398 5444) of the Department.
Yours faithfully,
(Miss Bonny CHAO)
for Director-General of Trade and Industry
Note : While every effort is made to ensure the accuracy of the above information, the Department cannot guarantee this to be so and will not be held liable for any reliance placed on the same.